No Data
No Data
Biophytis Deploys Its Partnership Strategy and Signs Two Contracts With Local Agents in Asia
Biophytis Obtains IND Approval From the FDA to Start Its Phase 2 OBA Study in Obesity
Biophytis Presented Its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris
6-K: Report of foreign private issuer (related to financial reporting)
Biophytis Grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million
Biophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by Its Service Provider Seqens
No Data